UPDATE: Jefferies Raises PT to $46 on BioMarin Pharmaceutical Ahead of GALNS Data
Jefferies reiterated its Buy rating on BioMarin Pharmaceutical (NASDAQ: BMRN) and raised its price target from $44 to $46.
Jefferies said, "Our experts discussions indicate probability of successful GALNS Ph3 for Morquio A syndrome (MPS IV) at ~60%-85%. If successful, we forecast ~25-30% upside from current levels (& BMRN will likely continue to trade up on additional pipeline potential). BMRN expects GALNS BLA filing in 1Q13, with potentially regulatory approval by 4Q13. We forecast GALNS to turn BMRN to profitability, with peak annual sales potential of ~$500M."
BioMarin Pharmaceutical closed at $38.87 on Tuesday.
Latest Ratings for BMRN
|Nov 2016||Deutsche Bank||Initiates Coverage On||Buy|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.